Journal: Frontiers in Microbiology

Article Title: Genetic characterization of MDR genomic elements carrying two aac(6′) - aph(2″) genes in feline-derived clinical Enterococcus faecalis isolate

doi: 10.3389/fmicb.2023.1191837

Figure Lengend Snippet: MICs of different antibiotics against the E. faecalis ESC1 and its transconjugants.

Article Snippet: ATCC 25922 transconjugants , 64 , – , 128 , – , – , 0.125 , 2 , 0.125 , 128 , 64.

Techniques:

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Transfer of Plasmid-Mediated CTX-M-9 from Salmonella enterica Serotype Virchow to Enterobacteriaceae in Human Flora-Associated Rats Treated with Cefixime ▿

doi: 10.1128/AAC.00310-09

Figure Lengend Snippet: Antibiotic susceptibilities of the strains used in this study

Article Snippet: Cotransfer of other genes conferring resistance to nalidixic acid, streptomycin, tetracycline, trimethoprim, sulfamethoxazole, or trimethoprim-sulfamethoxazole was not observed. table ft1 table-wrap mode="anchored" t5 TABLE 2. caption a7 Antibiotic(s) E. coli ATCC 25922 Donor S. enterica serotype Virchow 3464b Recipient E. coli J5 E. coli J5 transconjugants a Control Cefixime Cefixime-clavulanic acid Amoxicillin-clavulanic acid 4 b 8 4 16 8-32 8-16 Ampicillin 4 128 4 16 16-32 16 Cefixime 0.125 8 0.125 8 8 8 Cefotaxime 0.03 >8 0.03 0.5 0.5 0.5 Cefoxitin 4 16 4 8-32 16 16-128 Ceftazidime 0.125 8 0.125 1-4 1 1 Ceftiofur 0.25 >8 0.25 1-8 1 1 Cefuroxime 2 >32 2 16-32 8-16 16-32 Nalidixic acid 4 256 4 4 4 4 Rifampin 4 4 >512 >512 >512 >512 Streptomycin 2 128 2 2 2 2 Sulfamethoxazole 8 >512 8 4-8 4-8 4-8 Tetracycline 1 64 1 2-4 2 4 Trimethoprim 0.5 >64 0.5 0.5 0.5-2 1 Trimethoprim-sulfamethoxazole <1 >16 <1 1 1 1 Open in a separate window a Five of 15 E. coli J5 transconjugants isolated from animals treated with water (control), cefixime, or cefixime-clavulanic acid were tested to determine the MICs of antibiotics. b MICs are expressed in μg/ml.

Techniques:

Journal:

Article Title: A Novel Complex Mutant ?-Lactamase, TEM-68, Identified in a Klebsiella pneumoniae Isolate from an Outbreak of Extended-Spectrum ?-Lactamase-Producing Klebsiellae

doi:

Figure Lengend Snippet: Antimicrobial susceptibilities of clinical isolates and transconjugants

Article Snippet: Susceptibility patterns of transconjugants correlated with the data obtained for the corresponding clinical isolates. table ft1 table-wrap mode="anchored" t5 TABLE 3 caption a7 Strain (PFGE type, pI of ESBL) No. of isolates MIC(s) (μg/ml) or range of MICs AMP a PIP PIP-TAZ CTX CTX-CLAV CAZ CAZ-CLAV ATM ATM-CLAV FOX IPM AK GN K. pneumoniae (a, 5.7) 1 >512 >512 >512 32 8 256 128 256 64 32 0.25 2 128 K. pneumoniae (a, 6.0) 8 >512 >512 2–4 8–16 ≤0.03–0.06 128 0.25–0.5 128 0.125 2–4 0.125 1–2 32, 128 K. pneumoniae (d, 6.0) 3 >512 >512 32 16 0.125–0.25 128 1 256 0.25 8 0.125 1 32 K. pneumoniae (b2, 6.0) 2 >512 >512 4–8 16 0.06–0.125 64–128 0.5–1 128–256 0.125–0.25 4–8 0.125 1 32–64 K. pneumoniae (b2, 8.2) 1 >512 128 4 8 0.125 128 0.5 256 0.125 4 0.125 16 4 K. pneumoniae (b1, 8.2) 5 >512 256 4–8 8–16 0.125–0.25 128 0.5–1 256 0.125–0.25 4–8 0.125 8–16 4–8 K. pneumoniae (c, 8.2) 2 >512 256 16 8 0.25 128–256 0.5–1 256–512 0.125 16 0.125–0.25 8 4 K. oxytoca (8.2) 2 512–>512 64 0.5–1 1–2 ≤0.03 8 0.125 8–16 ≤0.03 1 0.125 16 4–8 K. pneumoniae R + b (6.0) 11 >512 64–128 0.5 2–4 ≤0.03 8 0.06–0.125 8–16 ≤0.03 1–2 0.125 0.5 16–32 K. pneumoniae , K. oxytoca R + (8.2) 7 256 16–32 0.5 1 ≤0.03 8 0.125 16 ≤0.03 1–2 0.125 4–8 2 E. coli A15 R − 2 ≤0.5 ≤0.5 ≤0.03 ≤0.03 0.125 0.125 0.06 ≤0.03 1 0.125 0.5 0.25 E. coli ATCC 25922 4 2 2 0.06 ≤0.03 0.25 0.125 0.06 0.06 4 0.125 1 0.5 Open in a separate window a AMP, ampicillin; PIP, piperacillin; CTX, cefotaxime; CAZ, ceftazidime; ATM, aztreonam; FOX, cefoxitin; IPM, imipenem; TAZ, tazobactam (4 μg/ml); CLAV, clavulanate (2 μg/ml); AK, amikacin; GN, gentamicin. b R + , transconjugants.

Techniques:

Journal:

Article Title: A Novel Complex Mutant ?-Lactamase, TEM-68, Identified in a Klebsiella pneumoniae Isolate from an Outbreak of Extended-Spectrum ?-Lactamase-Producing Klebsiellae

doi:

Figure Lengend Snippet: Clinical data, RAPD patterns, PFGE types, plasmid fingerprints, IEF of β-lactamases, and ESBLs identified in klebsiella isolates and E. coli transconjugants

Article Snippet: Susceptibility patterns of transconjugants correlated with the data obtained for the corresponding clinical isolates. table ft1 table-wrap mode="anchored" t5 TABLE 3 caption a7 Strain (PFGE type, pI of ESBL) No. of isolates MIC(s) (μg/ml) or range of MICs AMP a PIP PIP-TAZ CTX CTX-CLAV CAZ CAZ-CLAV ATM ATM-CLAV FOX IPM AK GN K. pneumoniae (a, 5.7) 1 >512 >512 >512 32 8 256 128 256 64 32 0.25 2 128 K. pneumoniae (a, 6.0) 8 >512 >512 2–4 8–16 ≤0.03–0.06 128 0.25–0.5 128 0.125 2–4 0.125 1–2 32, 128 K. pneumoniae (d, 6.0) 3 >512 >512 32 16 0.125–0.25 128 1 256 0.25 8 0.125 1 32 K. pneumoniae (b2, 6.0) 2 >512 >512 4–8 16 0.06–0.125 64–128 0.5–1 128–256 0.125–0.25 4–8 0.125 1 32–64 K. pneumoniae (b2, 8.2) 1 >512 128 4 8 0.125 128 0.5 256 0.125 4 0.125 16 4 K. pneumoniae (b1, 8.2) 5 >512 256 4–8 8–16 0.125–0.25 128 0.5–1 256 0.125–0.25 4–8 0.125 8–16 4–8 K. pneumoniae (c, 8.2) 2 >512 256 16 8 0.25 128–256 0.5–1 256–512 0.125 16 0.125–0.25 8 4 K. oxytoca (8.2) 2 512–>512 64 0.5–1 1–2 ≤0.03 8 0.125 8–16 ≤0.03 1 0.125 16 4–8 K. pneumoniae R + b (6.0) 11 >512 64–128 0.5 2–4 ≤0.03 8 0.06–0.125 8–16 ≤0.03 1–2 0.125 0.5 16–32 K. pneumoniae , K. oxytoca R + (8.2) 7 256 16–32 0.5 1 ≤0.03 8 0.125 16 ≤0.03 1–2 0.125 4–8 2 E. coli A15 R − 2 ≤0.5 ≤0.5 ≤0.03 ≤0.03 0.125 0.125 0.06 ≤0.03 1 0.125 0.5 0.25 E. coli ATCC 25922 4 2 2 0.06 ≤0.03 0.25 0.125 0.06 0.06 4 0.125 1 0.5 Open in a separate window a AMP, ampicillin; PIP, piperacillin; CTX, cefotaxime; CAZ, ceftazidime; ATM, aztreonam; FOX, cefoxitin; IPM, imipenem; TAZ, tazobactam (4 μg/ml); CLAV, clavulanate (2 μg/ml); AK, amikacin; GN, gentamicin. b R + , transconjugants.

Techniques: Plasmid Preparation, Isolation, Sequencing

Journal:

Article Title: A Novel Complex Mutant ?-Lactamase, TEM-68, Identified in a Klebsiella pneumoniae Isolate from an Outbreak of Extended-Spectrum ?-Lactamase-Producing Klebsiellae

doi:

Figure Lengend Snippet: Antimicrobial susceptibilities of clinical isolates and transconjugants

Article Snippet: Susceptibility patterns of transconjugants correlated with the data obtained for the corresponding clinical isolates. table ft1 table-wrap mode="anchored" t5 TABLE 3 caption a7 Strain (PFGE type, pI of ESBL) No. of isolates MIC(s) (μg/ml) or range of MICs AMP a PIP PIP-TAZ CTX CTX-CLAV CAZ CAZ-CLAV ATM ATM-CLAV FOX IPM AK GN K. pneumoniae (a, 5.7) 1 >512 >512 >512 32 8 256 128 256 64 32 0.25 2 128 K. pneumoniae (a, 6.0) 8 >512 >512 2–4 8–16 ≤0.03–0.06 128 0.25–0.5 128 0.125 2–4 0.125 1–2 32, 128 K. pneumoniae (d, 6.0) 3 >512 >512 32 16 0.125–0.25 128 1 256 0.25 8 0.125 1 32 K. pneumoniae (b2, 6.0) 2 >512 >512 4–8 16 0.06–0.125 64–128 0.5–1 128–256 0.125–0.25 4–8 0.125 1 32–64 K. pneumoniae (b2, 8.2) 1 >512 128 4 8 0.125 128 0.5 256 0.125 4 0.125 16 4 K. pneumoniae (b1, 8.2) 5 >512 256 4–8 8–16 0.125–0.25 128 0.5–1 256 0.125–0.25 4–8 0.125 8–16 4–8 K. pneumoniae (c, 8.2) 2 >512 256 16 8 0.25 128–256 0.5–1 256–512 0.125 16 0.125–0.25 8 4 K. oxytoca (8.2) 2 512–>512 64 0.5–1 1–2 ≤0.03 8 0.125 8–16 ≤0.03 1 0.125 16 4–8 K. pneumoniae R + b (6.0) 11 >512 64–128 0.5 2–4 ≤0.03 8 0.06–0.125 8–16 ≤0.03 1–2 0.125 0.5 16–32 K. pneumoniae , K. oxytoca R + (8.2) 7 256 16–32 0.5 1 ≤0.03 8 0.125 16 ≤0.03 1–2 0.125 4–8 2 E. coli A15 R − 2 ≤0.5 ≤0.5 ≤0.03 ≤0.03 0.125 0.125 0.06 ≤0.03 1 0.125 0.5 0.25 E. coli ATCC 25922 4 2 2 0.06 ≤0.03 0.25 0.125 0.06 0.06 4 0.125 1 0.5 Open in a separate window a AMP, ampicillin; PIP, piperacillin; CTX, cefotaxime; CAZ, ceftazidime; ATM, aztreonam; FOX, cefoxitin; IPM, imipenem; TAZ, tazobactam (4 μg/ml); CLAV, clavulanate (2 μg/ml); AK, amikacin; GN, gentamicin. b R + , transconjugants.

Techniques:

Journal:

Article Title: A Novel Complex Mutant ?-Lactamase, TEM-68, Identified in a Klebsiella pneumoniae Isolate from an Outbreak of Extended-Spectrum ?-Lactamase-Producing Klebsiellae

doi:

Figure Lengend Snippet: Antimicrobial susceptibilities of clinical isolates and E. coli transformants producing TEM-47 and TEM-68

Article Snippet: Susceptibility patterns of transconjugants correlated with the data obtained for the corresponding clinical isolates. table ft1 table-wrap mode="anchored" t5 TABLE 3 caption a7 Strain (PFGE type, pI of ESBL) No. of isolates MIC(s) (μg/ml) or range of MICs AMP a PIP PIP-TAZ CTX CTX-CLAV CAZ CAZ-CLAV ATM ATM-CLAV FOX IPM AK GN K. pneumoniae (a, 5.7) 1 >512 >512 >512 32 8 256 128 256 64 32 0.25 2 128 K. pneumoniae (a, 6.0) 8 >512 >512 2–4 8–16 ≤0.03–0.06 128 0.25–0.5 128 0.125 2–4 0.125 1–2 32, 128 K. pneumoniae (d, 6.0) 3 >512 >512 32 16 0.125–0.25 128 1 256 0.25 8 0.125 1 32 K. pneumoniae (b2, 6.0) 2 >512 >512 4–8 16 0.06–0.125 64–128 0.5–1 128–256 0.125–0.25 4–8 0.125 1 32–64 K. pneumoniae (b2, 8.2) 1 >512 128 4 8 0.125 128 0.5 256 0.125 4 0.125 16 4 K. pneumoniae (b1, 8.2) 5 >512 256 4–8 8–16 0.125–0.25 128 0.5–1 256 0.125–0.25 4–8 0.125 8–16 4–8 K. pneumoniae (c, 8.2) 2 >512 256 16 8 0.25 128–256 0.5–1 256–512 0.125 16 0.125–0.25 8 4 K. oxytoca (8.2) 2 512–>512 64 0.5–1 1–2 ≤0.03 8 0.125 8–16 ≤0.03 1 0.125 16 4–8 K. pneumoniae R + b (6.0) 11 >512 64–128 0.5 2–4 ≤0.03 8 0.06–0.125 8–16 ≤0.03 1–2 0.125 0.5 16–32 K. pneumoniae , K. oxytoca R + (8.2) 7 256 16–32 0.5 1 ≤0.03 8 0.125 16 ≤0.03 1–2 0.125 4–8 2 E. coli A15 R − 2 ≤0.5 ≤0.5 ≤0.03 ≤0.03 0.125 0.125 0.06 ≤0.03 1 0.125 0.5 0.25 E. coli ATCC 25922 4 2 2 0.06 ≤0.03 0.25 0.125 0.06 0.06 4 0.125 1 0.5 Open in a separate window a AMP, ampicillin; PIP, piperacillin; CTX, cefotaxime; CAZ, ceftazidime; ATM, aztreonam; FOX, cefoxitin; IPM, imipenem; TAZ, tazobactam (4 μg/ml); CLAV, clavulanate (2 μg/ml); AK, amikacin; GN, gentamicin. b R + , transconjugants.

Techniques:

Journal:

Article Title: A Novel Complex Mutant ?-Lactamase, TEM-68, Identified in a Klebsiella pneumoniae Isolate from an Outbreak of Extended-Spectrum ?-Lactamase-Producing Klebsiellae

doi:

Figure Lengend Snippet: MICs of piperacillin combined with various concentrations of clavulanate and tazobactam for TEM-47- and TEM-68-producing klebsiella clinical isolates and E. coli transformants

Article Snippet: Susceptibility patterns of transconjugants correlated with the data obtained for the corresponding clinical isolates. table ft1 table-wrap mode="anchored" t5 TABLE 3 caption a7 Strain (PFGE type, pI of ESBL) No. of isolates MIC(s) (μg/ml) or range of MICs AMP a PIP PIP-TAZ CTX CTX-CLAV CAZ CAZ-CLAV ATM ATM-CLAV FOX IPM AK GN K. pneumoniae (a, 5.7) 1 >512 >512 >512 32 8 256 128 256 64 32 0.25 2 128 K. pneumoniae (a, 6.0) 8 >512 >512 2–4 8–16 ≤0.03–0.06 128 0.25–0.5 128 0.125 2–4 0.125 1–2 32, 128 K. pneumoniae (d, 6.0) 3 >512 >512 32 16 0.125–0.25 128 1 256 0.25 8 0.125 1 32 K. pneumoniae (b2, 6.0) 2 >512 >512 4–8 16 0.06–0.125 64–128 0.5–1 128–256 0.125–0.25 4–8 0.125 1 32–64 K. pneumoniae (b2, 8.2) 1 >512 128 4 8 0.125 128 0.5 256 0.125 4 0.125 16 4 K. pneumoniae (b1, 8.2) 5 >512 256 4–8 8–16 0.125–0.25 128 0.5–1 256 0.125–0.25 4–8 0.125 8–16 4–8 K. pneumoniae (c, 8.2) 2 >512 256 16 8 0.25 128–256 0.5–1 256–512 0.125 16 0.125–0.25 8 4 K. oxytoca (8.2) 2 512–>512 64 0.5–1 1–2 ≤0.03 8 0.125 8–16 ≤0.03 1 0.125 16 4–8 K. pneumoniae R + b (6.0) 11 >512 64–128 0.5 2–4 ≤0.03 8 0.06–0.125 8–16 ≤0.03 1–2 0.125 0.5 16–32 K. pneumoniae , K. oxytoca R + (8.2) 7 256 16–32 0.5 1 ≤0.03 8 0.125 16 ≤0.03 1–2 0.125 4–8 2 E. coli A15 R − 2 ≤0.5 ≤0.5 ≤0.03 ≤0.03 0.125 0.125 0.06 ≤0.03 1 0.125 0.5 0.25 E. coli ATCC 25922 4 2 2 0.06 ≤0.03 0.25 0.125 0.06 0.06 4 0.125 1 0.5 Open in a separate window a AMP, ampicillin; PIP, piperacillin; CTX, cefotaxime; CAZ, ceftazidime; ATM, aztreonam; FOX, cefoxitin; IPM, imipenem; TAZ, tazobactam (4 μg/ml); CLAV, clavulanate (2 μg/ml); AK, amikacin; GN, gentamicin. b R + , transconjugants.

Techniques: